Biotech Bonanza of 2012
So far, 2012 has been a terrific year for our biotechnology portfolio. It's been great for biotech investors in general, despite the weak global economy.
The NASDAQ Biotechnology Index (NBI), for example, is up 35%. Our newsletter's biotech picks, however, have outperformed even these stellar returns.
Of the stocks we picked before January of this year, the average year to date return has been 58%. If we include our new picks, the figure comes out to 44.8%, year to date.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.